QuiaPEG

Newsroom

May 18, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops improved versions of clinically validated or already approved drugs, today announced it signed an agreement with the Chinese pharmaceutical company Chengdu Shengnuo Biopharm Co.,Ltd (”SNBio”), which pays $200,000 (approx. 2 MSEK) in exchange for being able to evaluate for a limited time a proprietary drug together with one of QuiaPEG's releasable activated PEGs from the technology platform Uni-Qleaver®.

Download press release (PDF)

Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message